Pfizer Ltd
PFIZERPfizer Ltd
PFIZER
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.14 | 6.73 | 0.66% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Pfizer Limited is a pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,109.22 | 2,197.85 | 2,082.80 | 2,248.89 | 2,335.67 | 2,319.67 | 2,673.64 | 2,558.81 | 2,381.63 | 2,441.89 | ||||||||||
Raw Materials | 735.20 | 812.24 | 712.17 | 838.78 | 829.02 | 783.39 | 1,020.93 | 817.19 | 804.39 | 1,529.33 | ||||||||||
| Power & Fuel Cost | 10.43 | 10.34 | 12.34 | 11.45 | 11.04 | 5.79 | 5.67 | 6.51 | 3.98 | |||||||||||
| Employee Cost | 277.34 | 303.89 | 314.29 | 323.84 | 364.51 | 361.06 | 403.67 | 331.68 | 347.80 | |||||||||||
| Selling & Administrative Expenses | 375.97 | 383.12 | 316.73 | 335.32 | 319.66 | 268.67 | 310.77 | 298.03 | 317.96 | |||||||||||
| Operating & Other expenses | 180.53 | 106.54 | 112.34 | 6.48 | 54.70 | 107.24 | 34.01 | 162.40 | 83.72 | |||||||||||
EBITDA | 529.75 | 581.72 | 614.93 | 733.02 | 756.74 | 793.52 | 898.59 | 943.00 | 823.78 | 912.56 | ||||||||||
| Depreciation/Amortization | 57.93 | 62.93 | 66.25 | 71.39 | 103.24 | 109.41 | 115.00 | 105.51 | 62.28 | 60.89 | ||||||||||
| PBIT | 471.82 | 518.79 | 548.68 | 661.63 | 653.50 | 684.11 | 783.59 | 837.49 | 761.50 | 851.67 | ||||||||||
| Interest & Other Items | 1.40 | 1.96 | 0.77 | 1.72 | 11.01 | 15.39 | 10.70 | 13.48 | 15.43 | 14.02 | ||||||||||
| PBT | 470.42 | 516.83 | 547.91 | 659.91 | 642.49 | 668.72 | 772.89 | 824.01 | 746.07 | 837.65 | ||||||||||
| Taxes & Other Items | 165.44 | 180.05 | 187.84 | 230.86 | 133.36 | 171.11 | 160.33 | 200.08 | 194.74 | 219.75 | ||||||||||
| Net Income | 304.98 | 336.78 | 360.07 | 429.05 | 509.13 | 497.61 | 612.56 | 623.93 | 551.33 | 617.90 | ||||||||||
| EPS | 66.66 | 73.61 | 78.70 | 93.78 | 111.28 | 108.76 | 133.88 | 136.37 | 120.50 | 135.05 | ||||||||||
| DPS | 15.00 | 20.00 | 20.00 | 22.50 | 330.00 | 35.00 | 35.00 | 70.00 | 35.00 | 35.00 | ||||||||||
| Payout ratio | 0.23 | 0.27 | 0.25 | 0.24 | 2.97 | 0.32 | 0.26 | 0.51 | 0.29 | 0.26 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Pfizer Ltd | 43.87 | 6.73 | 0.66% |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare PFIZER with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.11%
Top 5 Mutual Funds holding Pfizer Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.3583% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/238 (+104) |
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.8331% | Percentage of the fund’s portfolio invested in the stock 1.69% | Change in the portfolio weight of the stock over the last 3 months 1.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 54/94 (+13) |
SBI Innovative Opportunities Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9042% | Percentage of the fund’s portfolio invested in the stock 2.69% | Change in the portfolio weight of the stock over the last 3 months 2.69% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/38 (-5) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 0.66%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.58 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 21, 2024
Dividend/Share
₹35.00
Ex DateEx Date
Aug 21, 2024
Cash Dividend
Ex DateEx DateAug 11, 2023
Dividend/Share
₹35.00
Ex DateEx Date
Aug 11, 2023
Cash Dividend
Ex DateEx DateAug 11, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 11, 2023
Cash Dividend
Ex DateEx DateSep 19, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateAug 18, 2022
Dividend/Share
₹35.00
Ex DateEx Date
Aug 18, 2022
Net profit of Pfizer rose 6.30% to Rs 158.35 crore in the quarter ended September 2024 as against Rs 148.96 crore during the previous quarter ended September 2023. Sales rose 2.33% to Rs 588.59 crore in the quarter ended September 2024 as against Rs 575.21 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales588.59575.21 2 OPM %32.1531.75 - PBDT230.22215.95 7 PBT215.23200.52 7 NP158.35148.96 6 Powered by Capital Market - Live
Pfizer will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
Pfizer announced that the Annual General Meeting (AGM) of the company will be held on 28 August 2024.Powered by Capital Market - Live
Pfizer raises annual profit forecast on strong sales of cancer, heart drugs
Pfizer standalone net profit rises 61.14% in the June 2024 quarter
Pfizer Q1 Results Review - On A Recovery Path, Growth Should Strengthen: Systematix
Net profit of Pfizer rose 61.14% to Rs 150.71 crore in the quarter ended June 2024 as against Rs 93.53 crore during the previous quarter ended June 2023. Sales rose 5.93% to Rs 562.86 crore in the quarter ended June 2024 as against Rs 531.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales562.86531.36 6 OPM %31.5320.84 - PBDT217.22141.30 54 PBT202.62125.75 61 NP150.7193.53 61 Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 1.15%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.02% to 0.63%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 5.14%, vs industry avg of 15.28%